CoChat

Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Open access
Ali, Mahmoud M., Hafez, Ahmed, Abdelgalil, Mahmoud Shaban, Hasan, Mohammed Tarek, El-Ghannam, Mohammed Magdy, Ghogar, Osama M., Elrashedy, Asmaa Ahmed, Abd-ElGawad, Mohamed · 2022 · BMC Endocrine Disorders

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Background: The food and drug administration approved many drugs to treat diabetes mellitus, but those drugs do not have a noticeable effect on weight management. Recently, glucagon-like peptide 1 agonist known as Cotadutide serve as a potent drug in treating type 2 diabetes by reducing blood glucose levels and body weight indices. This study aimed to explore the safety and efficacy of Cotadutide as a treatment for type 2 diabetes individuals. Methods: A comprehensive literature search was done on different databases, including PubMed, Scopus, Web of Science, and Cochrane Library to capture all relevant articles using an established search strategy. The inclusion criteria were randomized controlled trials that assessed the safety and efficacy of Cotadutide versus placebo or any anti-diabetes drugs in patients with type 2 diabetes mellitus and a BMI between 22 kg/m 2 and 40 kg/m 2. We conducted the analysis using Revman software version 5.4. Results: We found 663 relevant articles. From which nine studies were included and subjected to qualitative analysis and eight for quantitative analysis. The pooled effect showed that Cotadutide was better than placebo in reducing body weight (kg) (Mean difference (MD) = 3.31, p < 0.00001), glycated hemoglobin (HbA 1c) (MD = 0.68, p > 0.00001), glucose area under the plasma concentration curve (AUC [0-4 h]) (MD = 30.15, p < 0.00001), and fasting plasma glucose over time (mg/dl) (MD = 31.31, p < 0.00001). Conclusion: Cotadutide is safe and effective in reducing plasma glucose levels, HbA 1c and body weight in individuals with type 2 diabetes. Trial registration: The study protocol was registered on PROSPERO (CRD: CRD42021257670).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12902-022-01031-5

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)CC BY · PubMed Central
Fig. 2 Risk of bias graph for randomized controlled trials using Excel tool to implement Rob2
Fig. 2 Risk of bias graph for randomized controlled trials using Excel tool to implement Rob2CC BY · PubMed Central
Fig. 3 Risk of bias summary for randomized controlled trials using Excel tool to implement Rob2
Fig. 3 Risk of bias summary for randomized controlled trials using Excel tool to implement Rob2CC BY · PubMed Central
Fig. 4 Percentage decrease in body weight plot
Fig. 4 Percentage decrease in body weight plotCC BY · PubMed Central
Fig. 5 Decrease from baseline in Glycated Haemoglobin (HbA1c) plot
Fig. 5 Decrease from baseline in Glycated Haemoglobin (HbA1c) plotCC BY · PubMed Central
Fig. 6 percentage decrease in glucose area under the plasma concentration curve (AUC [0-4 h]) plot
Fig. 6 percentage decrease in glucose area under the plasma concentration curve (AUC [0-4 h]) plotCC BY · PubMed Central
Fig. 7 Change from Baseline in Fasting Plasma Glucose over Time (mg/dl) plot
Fig. 7 Change from Baseline in Fasting Plasma Glucose over Time (mg/dl) plotCC BY · PubMed Central
Fig. 8 Treatment-Emergent Adverse Events (TEAEs) plot
Fig. 8 Treatment-Emergent Adverse Events (TEAEs) plotCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 24

Metadata

Authors
Ali, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd-ElGawad, M.
Affiliations
  • Al-Azhar University (EG)
  • German University in Cairo (EG)
  • Kafrelsheikh University (EG)
Venue
BMC Endocrine Disorders
Published
2022-04-29
Volume
22
Issue
1
Pages
113-113
ISSN
1472-6823 (ISSN-L)
OpenAlex
W4225098447
Cited by
23
References
35
Citations by year
2026: 1 · 2025: 5 · 2024: 6 · 2023: 9 · 2022: 2
FWCI
0.78
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Endocrine Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
The Science, Technology & Innovation Funding Authority
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
cotadutide, type 2 diabetes, GLP-1 receptor agonists, weight loss, HbA1c, fasting blood glucose, glycemic control, drug safety and efficacy
MeSH terms
Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Pharmaceutical Preparations, Humans, Peptides, United States, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12902-022-01031-5
The paper
Ali, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd-ElGawad, M. (2022). Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-022-01031-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.